3',4'-Methylenedioxy-α-pyrrolidinopropiophenone

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP) is a stimulant designer drug. It was sold in Germany in the late 1990s and early 2000s as an ingredient in imitation ecstasy (MDMA) pills.[1] It shares a similar chemical structure with α-PPP and MDPV,[2][3][4] and has been shown to have reinforcing effects in rats.[5]

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone
Clinical data
Routes of
administration		oral, insufflation, Vaporization, IV, rectal, sublingual
Legal status
Legal status
  • DE: Anlage I (Authorized scientific use only)
  • UK: Class B
Pharmacokinetic data
MetabolismHepatic
ExcretionPrimarily Urine (Renal)
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC14H17NO3
Molar mass247.28 g/mol g·mol−1
3D model (JSmol)
ChiralityRacemic mixture

Metabolism

MDPPP appears to have a similar metabolic fate as MDPV.[4]

As of October 2015 MDPPP is a controlled substance in China.[6]

See also

References
  1. Springer, D.; Fritschi, G.; Maurer, H. H. (2003). "Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxy-α-pyrrolidinopropiophenone studied in urine using gas chromatography–mass spectrometry". Journal of Chromatography B. 793 (2): 377. doi:10.1016/S1570-0232(03)00350-7.
  2. Maurer, HH; Kraemer, T; Springer, D; Staack, RF (2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic drug monitoring. 26 (2): 127–31. doi:10.1097/00007691-200404000-00007. PMID 15228152.
  3. Staack, RF; Maurer, HH (2005). "Metabolism of designer drugs of abuse". Current Drug Metabolism. 6 (3): 259–74. doi:10.2174/1389200054021825. PMID 15975043.
  4. Springer, D; Staack, RF; Paul, LD; Kraemer, T; Maurer, HH (2005). "Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes". Xenobiotica. 35 (3): 227–37. doi:10.1080/00498250400028239. PMID 16019948.
  5. Gannon, BM; Galindo, KI; Mesmin, MP; Sulima, A; Rice, KC; Collins, GT (12 August 2017). "Relative reinforcing effects of second-generation synthetic cathinones: Acquisition of self-administration and fixed ratio dose-response curves in rats". Neuropharmacology. doi:10.1016/j.neuropharm.2017.08.018. PMC 5809320. PMID 28811192.
  6. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.